Stocks
FibroGen Financial Statements (FGEN) |
||||||||||
| FibroGensmart-lab.ru | % | 2020 | 2021 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2021 | 28.02.2022 | 04.03.2022 | 27.02.2023 | 26.02.2024 | 12.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 176.3 | 235.3 | 235.3 | 140.7 | 147.8 | 180.0 | |||
| Operating Income, bln rub | -191.9 | -288.5 | -288.5 | -301.0 | -281.8 | -113.0 | ||||
| EBITDA, bln rub | ? | -164.3 | -274.8 | -288.5 | -282.8 | -261.4 | -99.9 | |||
| Net profit, bln rub | ? | -189.3 | -291.0 | -291.0 | -295.2 | -284.2 | -121.8 | |||
| OCF, bln rub | ? | 81.6 | -82.2 | -82.2 | -145.9 | -315.0 | -125.9 | |||
| CAPEX, bln rub | ? | 3.99 | 30.2 | 30.2 | 38.7 | 2.52 | 0.376 | |||
| FCF, bln rub | ? | 77.6 | -112.4 | -112.4 | -184.7 | -317.5 | -126.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 2.26 | 2.26 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.85% | ||||
| OPEX, bln rub | 359.3 | 511.0 | 511.0 | 421.5 | 398.1 | 232.8 | ||||
| Cost of production, bln rub | 8.87 | 12.9 | 12.9 | 20.3 | 18.8 | 41.6 | ||||
| R&D, bln rub | 252.9 | 387.0 | 387.0 | 296.8 | 282.9 | 145.9 | ||||
| Interest expenses, bln rub | 2.40 | 2.15 | 2.15 | 1.44 | 15.5 | 21.1 | ||||
| Assets, bln rub | 826.8 | 773.8 | 773.8 | 610.1 | 423.5 | 264.4 | ||||
| Net Assets, bln rub | ? | 422.2 | 209.1 | 209.1 | -21.4 | -204.2 | -201.7 | |||
| Debt, bln rub | 37.7 | 99.7 | 99.7 | 89.9 | 170.5 | 2.00 | ||||
| Cash, bln rub | 686.5 | 405.2 | 405.2 | 422.0 | 235.6 | 131.0 | ||||
| Net debt, bln rub | -648.8 | -305.5 | -305.5 | -332.1 | -65.1 | -129.0 | ||||
| Ordinary share price, rub | 37.1 | 14.1 | 14.1 | 16.0 | 0.886 | 0.550 | ||||
| Number of ordinary shares, mln | 89.9 | 92.3 | 92.3 | 93.6 | 97.3 | 100.5 | ||||
| Market cap, bln rub | 3 333 | 1 302 | 1 302 | 1 499 | 86 | 55 | ||||
| EV, bln rub | ? | 2 684 | 997 | 997 | 1 167 | 21 | -74 | |||
| Book value, bln rub | 422 | 209 | 209 | -21 | -204 | -202 | ||||
| EPS, rub | ? | -2.11 | -3.15 | -3.15 | -3.15 | -2.92 | -1.21 | |||
| FCF/share, rub | 0.86 | -1.22 | -1.22 | -1.97 | -3.26 | -1.26 | ||||
| BV/share, rub | 4.70 | 2.26 | 2.26 | -0.23 | -2.10 | -2.01 | ||||
| EBITDA margin, % | ? | -93.2% | -116.8% | -122.6% | -201.0% | -176.9% | -55.5% | |||
| Net margin, % | ? | -107.4% | -123.7% | -123.7% | -209.8% | -192.4% | -67.7% | |||
| FCF yield, % | ? | 2.33% | -8.63% | -8.63% | -12.3% | -368.2% | -228.3% | |||
| ROE, % | ? | -44.8% | -139.2% | -139.2% | 1 377% | 139.2% | 60.4% | |||
| ROA, % | ? | -22.9% | -37.6% | -37.6% | -48.4% | -67.1% | -46.1% | |||
| P/E | ? | -17.6 | -4.47 | -4.47 | -5.08 | -0.30 | -0.45 | |||
| P/FCF | 42.9 | -11.6 | -11.6 | -8.12 | -0.27 | -0.44 | ||||
| P/S | ? | 18.9 | 5.53 | 5.53 | 10.7 | 0.58 | 0.31 | |||
| P/BV | ? | 7.89 | 6.23 | 6.23 | -69.9 | -0.42 | -0.27 | |||
| EV/EBITDA | ? | -16.3 | -3.63 | -3.45 | -4.13 | -0.08 | 0.74 | |||
| Debt/EBITDA | 3.95 | 1.11 | 1.06 | 1.17 | 0.25 | 1.29 | ||||
| R&D/CAPEX, % | 6 333% | 1 282% | 1 282% | 766.1% | 11 229% | 38 806% | ||||
| CAPEX/Revenue, % | 2.27% | 12.8% | 12.8% | 27.5% | 1.70% | 0.21% | ||||
| FibroGen shareholders | ||||||||||
